Table 1 Patient characteristics

Outcome

 CR

96%

 Relapse

45%

 Death

33%

CBFB/MYH11

n = 162

 inv(16)

131 (81%)

 t(16;16)

16 (10%)

 CBFB/MYH11, not specified

15 (9%)

Type A fusion

90 (83%)

Nontype A fusion

13 (12%)

 Type D

7 (6%)

 Type E

4 (4%)

 Type S

2 (2%)

 Fusion not specified

53 (33%)

de novo AML

147 (91%)

 t-AML

13 (8%)

 s-AML

2 (1%)

Blasts in BM, median (range)

62% (10–95%)

 Blasts in PB, median (range)

47% (6–93%)

Age in years, median (range)

44 (17–83)

Male sex

54% (88/162)

Allogeneic HCT in 1st CR

 12 (7%)

RUNX1/RUNX1T1

n = 130

de novo AML

114 (88%)

 t-AML

12 (9%)

 s-AML

4 (3%)

Blasts in BM, median (range)

55% (10–90%)

 Blasts in PB, median (range)

44% (6–78%)

Age in years, median (range)

54 (16–79)

Male sex

60% (78/130)

 Allogeneic HCT in 1st CR

12 (9%)